RNF128 deficiency in macrophages promotes colonic inflammation by suppressing the autophagic degradation of S100A8

Xianwen Ran1,2, Yue Li2,3, Yahui Ren4

  • 1Department of Gastrointestinal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.

Cell Death & Disease
|January 14, 2025
PubMed

Insights

RNF128 is downregulated in inflammatory macrophages, worsening inflammatory bowel diseases (IBD). Restoring RNF128 function or targeting the RNF128-Tollip-S100A8 pathway may treat colitis.

Area of Science:

  • Immunology
  • Gastroenterology
  • Molecular Biology

Background:

  • Macrophages are crucial in intestinal homeostasis and inflammatory bowel diseases (IBDs).
  • Mechanisms governing macrophage-driven inflammation in IBD remain incompletely understood.
  • RNF128's role in macrophage function and intestinal inflammation is unexplored.

Purpose of the Study:

  • To investigate the role of RNF128 in regulating macrophage activity and intestinal inflammation.
  • To elucidate the molecular mechanisms by which RNF128 influences inflammatory responses.
  • To evaluate the therapeutic potential of targeting the RNF128 pathway in colitis models.

Main Methods:

  • Assessed RNF128 expression in proinflammatory macrophages.
  • Utilized in vitro assays to measure cytokine levels in RNF128-deficient cells.
  • Employed mouse models of IBD (DSS-induced colitis) and bone marrow transplantation.
  • Investigated the interaction of RNF128 with S100A8 and Tollip using biochemical assays.
  • Administered S100A8 neutralizing antibodies in mouse models.

Main Results:

  • RNF128 expression is decreased in proinflammatory macrophages.
  • RNF128 deficiency increases effector cytokine production and exacerbates IBD progression in mice.
  • RNF128 deficiency in bone marrow cells worsens DSS-induced colitis.
  • RNF128 promotes autophagic degradation of S100A8 via the cargo receptor Tollip.
  • S100A8 antibody treatment ameliorates colitis and improves survival in Rnf128-deficient mice.

Conclusions:

  • RNF128 acts as an anti-inflammatory factor in macrophages during colitis.
  • The RNF128-Tollip-S100A8 axis is a key regulator of intestinal inflammation.
  • Targeting this axis offers a potential therapeutic strategy for treating colitis and IBD.